Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
← catalyst calendarNCT06958211 · readout in 51 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
573actual
Sites
107
Countries
Belgium, Bulgaria, Canada +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-12 | actual | When the study began enrolling |
| Primary completion | 2026-10-09 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-07-11 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hidradenitis Suppurativa
Interventions
- Drug: Ruxolitinib Cream
- Drug: Vehicle Cream
Primary outcome
what the primary-completion date above is the date OFProportion of participants who achieve Hidradenitis Suppurativa (HS) Clinical Response 75 (HiSCR75) from baseline
measured Week 16
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed